Gelonghui, May 14 | Boji Pharmaceutical (300404.SZ) said on the investor interactive platform that the company has mastered a full chain of chemically synthesized peptide research and development technology, can provide one-stop CRO services for chemically synthesized peptide products, and is capable of undertaking research and development of innovative peptide drugs and high-end generic drug projects, not involving the field of synthetic biology.
博济医药(300404.SZ)：已掌握全链条的化学合成多肽研发技术 不涉及合成生物领域
Boji Pharmaceutical (300404.SZ): It has mastered a full chain of chemically synthesized peptide research and development technology, not involved in the field of synthetic biology
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.